{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GMCSF+%28granulocyte+macrophage+colony+stimulating+factor%29",
    "query": {
      "intervention": "GMCSF (granulocyte macrophage colony stimulating factor)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 507,
    "total_pages": 51,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GMCSF+%28granulocyte+macrophage+colony+stimulating+factor%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T15:08:58.700Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00487305",
      "title": "Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2007-06",
      "completion_date": "2023-07-25",
      "has_results": false,
      "last_update_posted_date": "2024-08-15",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00487305"
    },
    {
      "nct_id": "NCT02593123",
      "title": "Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin's Lymphoma",
        "Lymphoid Leukemia",
        "Lymphoma",
        "Leukemia",
        "Myeloma",
        "Acute Lymphocytic Leukemia",
        "Non Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Multiple Myeloma",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Recurrent Acute Myeloid Leukemia, Adult",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelogenous Leukemia",
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 31,
      "start_date": "2015-11-04",
      "completion_date": "2022-03-18",
      "has_results": true,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02593123"
    },
    {
      "nct_id": "NCT00003972",
      "title": "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 280,
      "start_date": "1998-07",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003972"
    },
    {
      "nct_id": "NCT04385277",
      "title": "Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ganglioneuroblastoma, Nodular",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dinutuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FDG-Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Iobenguane I-123",
          "type": "RADIATION"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Isotretinoin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 41,
      "start_date": "2020-12-31",
      "completion_date": "2027-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 70,
      "location_summary": "Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04385277"
    },
    {
      "nct_id": "NCT00003003",
      "title": "Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mitomycin C",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 29,
      "start_date": "1996-09",
      "completion_date": "2000-08",
      "has_results": false,
      "last_update_posted_date": "2018-03-19",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003003"
    },
    {
      "nct_id": "NCT00678054",
      "title": "Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 30,
      "start_date": "1999-04",
      "completion_date": "2015-10-23",
      "has_results": false,
      "last_update_posted_date": "2017-08-23",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00678054"
    },
    {
      "nct_id": "NCT00643097",
      "title": "Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasms of Brain"
      ],
      "interventions": [
        {
          "name": "PEP-3 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "John Sampson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2007-09",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00643097"
    },
    {
      "nct_id": "NCT01966289",
      "title": "SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "CY",
          "type": "DRUG"
        },
        {
          "name": "GVAX",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SGI-110",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-04-14",
      "completion_date": "2020-06-06",
      "has_results": false,
      "last_update_posted_date": "2021-03-30",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01966289"
    },
    {
      "nct_id": "NCT00004217",
      "title": "S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "valspodar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "56 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "56 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2000-02",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 89,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004217"
    },
    {
      "nct_id": "NCT00003958",
      "title": "Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Malignant Mesenchymoma",
        "Adult Rhabdomyosarcoma",
        "Alveolar Childhood Rhabdomyosarcoma",
        "Childhood Malignant Mesenchymoma",
        "Embryonal Childhood Rhabdomyosarcoma",
        "Embryonal-botryoid Childhood Rhabdomyosarcoma",
        "Nonmetastatic Childhood Soft Tissue Sarcoma",
        "Previously Untreated Childhood Rhabdomyosarcoma",
        "Stage I Adult Soft Tissue Sarcoma",
        "Stage II Adult Soft Tissue Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "dactinomycin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "Up to 49 Years"
      },
      "enrollment_count": 702,
      "start_date": "2002-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-17",
      "last_synced_at": "2026-10-04T15:08:58.700Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003958"
    }
  ]
}